Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
about
Neuroinflammatory responses in diabetic retinopathyInhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesityThe absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatmentGlucose, VEGF-A, and diabetic complicationsHyperglycemia-induced vasculopathy in the murine conceptus is mediated via reductions of VEGF-A expression and VEGF receptor activationReversal of experimental diabetic neuropathy by VEGF gene transferA novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesisRhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular developmentRegulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesisDiabetes regulates small molecular weight G-protein, H-Ras, in the microvasculature of the retina: implication in the development of retinopathyDiabetic retinopathy: current management and experimental therapeutic targets.Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body.Anti-inflammatory properties of C-Peptide.Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation.An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration.Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo.Molecular diversity of VEGF-A as a regulator of its biological activity.The pathogenesis of early retinal changes of diabetic retinopathy.Expectations in the treatment of retinal diseases: neuroprotection.Retinitis pigmentosa reduces the risk of proliferative diabetic retinopathy: a nationwide population-based cohort study.Angiogenesis impairment in diabetes: role of methylglyoxal-induced receptor for advanced glycation endproducts, autophagy and vascular endothelial growth factor receptor 2Diabetic retinopathy: targeting vasoregressionIncreased expression and activity of 12-lipoxygenase in oxygen-induced ischemic retinopathy and proliferative diabetic retinopathy: implications in retinal neovascularization.Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ.Elevated level of pro-inflammatory eicosanoids and EPC dysfunction in diabetic patients with cardiac ischemiaTNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosisEffects of restoring normoglycemia in type 1 diabetes on inflammatory profile and renal extracellular matrix structure after simultaneous pancreas and kidney transplantationAssociation of VEGF gene polymorphisms with diabetic retinopathy: a meta-analysis.Association of polymorphisms of angiotensin I converting enzyme 2 with retinopathy in type 2 diabetes mellitus among Chinese individualsVascular complications and gene therapy.The emerging role of the thioredoxin system in angiogenesisGrowth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy.Co-culture of Retinal and Endothelial Cells Results in the Modulation of Genes Critical to Retinal NeovascularizationHepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor.The MAPK signaling pathway mediates the GPR91-dependent release of VEGF from RGC-5 cells.Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing.Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers.Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial diseaseMultiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients
P2860
Q26798351-9334165B-656F-4835-BDF2-FD8D85BD2BA9Q26859210-DD983F2C-CAFE-4829-AB4E-A13E825176CAQ28353997-D8643F6F-A010-4A19-BDAB-9B861614877CQ28362039-8C818892-E4EB-4FA9-B126-0FA9554D43CDQ28362045-9C01B687-6A1E-43E8-9FE0-9CEC94BA5C59Q28364512-64B8B29C-E670-4C9E-B0C1-F116D2854012Q28476695-69E36E17-4875-49D9-BDEC-CC217E7FC5EAQ28512962-F1437FB8-A041-48A9-B26E-BE5FAC7E7053Q28513991-098EA058-14A0-4099-B7BF-3EC70FF3782DQ28577516-E2F36AD3-49E0-43B8-82B4-7DD010A6F3DAQ33403016-37490767-602E-4BB3-97A4-D1505AD04C0EQ33632180-D905976A-B1CE-475A-B80C-A69D95034CF9Q33682573-D1470C20-BA03-454C-B11D-77266619DFD2Q33834038-BA2282EA-0936-4007-89B0-A9B6EAC52762Q33943213-55851D46-D696-4D3F-AC11-AD2B6CF9BF8FQ34078704-EDBD0647-27A9-4549-931A-7213C7EFBAD0Q34089123-979C600A-15D1-4064-B8BA-0F53F401AAD5Q34149599-682C3EBF-AB9F-4F43-A928-AD73EC0BE67EQ34404709-1597AE89-F398-48FF-9948-2689A9043DA6Q34428315-0E4F4CB5-6567-432D-9301-28E10786A3C5Q34441960-CC1DC29C-6631-4CC2-B651-CC5E0F454862Q34448837-E5DEC2F2-8587-452C-94CE-7A23D877FA6FQ34527211-CC911E7A-8154-4D8F-B0C1-54726197F817Q34741796-0B11E692-FB94-4F4C-A523-5082BF85EB71Q34938962-AAA3FF47-3C65-42A4-B9E8-26902D1F75CBQ35005977-47D50F8B-0982-4BA9-BCCE-900BFC548A09Q35073484-C2A534BF-FE57-415B-B617-30377233687CQ35078329-F4B3B381-CBB7-4476-974D-C09EB4939473Q35088751-DF3368AA-C38B-41B8-85D3-62A68FE52263Q35116151-F85621E3-609C-46A9-98FA-1B1C11A9A722Q35123800-6189C304-9DAE-44FD-91B3-E7683BB05CA4Q35648554-67E3E4FE-DB94-4F94-A699-3FDB821B5BC1Q35658254-8BDAD9BC-F0FD-4756-A676-87FA8DD8C168Q35746501-A37178D1-1DA2-46F4-9DD8-CB8EDCDCEE98Q35791512-E674DAD3-D1CA-4D12-8B87-A2F713EA3AFFQ35827577-79F24A62-6AE1-46DB-9F1A-35FA6ADA3025Q35947546-3B45E73E-F491-45C5-BF00-E165865CA18EQ36117585-386D1F81-9CE3-4FF8-9251-5CDC671C0ED5Q36274594-36268C62-31E4-45CD-A2D4-8A4D358AD954Q36511716-B7514E32-D9A0-4886-8C9D-3C255A3B7963
P2860
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
@ast
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
@en
type
label
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
@ast
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
@en
prefLabel
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
@ast
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
@en
P1433
P1476
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
@en
P304
P356
10.2337/DIABETES.48.10.1899
P407
P577
1999-10-01T00:00:00Z